Clinical trial Recruiting at 1 site Interventional Ages 18 and up

High-flow nasal cannula versus noninvasive ventilation after extubation in people with systolic heart failure

Official title: A Prospective Randomized Controlled Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart Failure

Run by Yale University · NCT06671015 · Data updated 2026-11-12

This pilot will test whether high-flow nasal cannula or noninvasive ventilation after extubation better prevents reintubation in adults with systolic heart failure who were on a ventilator.

More Respiratory Failure trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorYale University
Academic / other
Locations1 site (New Haven, Connecticut)
StatusRecruiting
StartedOctober 4, 2025
Main results expectedJanuary 2027
Study endsFebruary 2027
Registry record updatedMay 28, 2026
Trial IDNCT06671015 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) with systolic left ventricular dysfunction (ejection fraction ≤40%) who have been mechanically ventilated for more than 24 hours and are ready for planned extubation in the CICU or MICU are ideal candidates.

Probably not a fit

Patients with active COPD exacerbation or chronic hypercapnia, pre-existing NIV prescriptions, tracheostomies, do-not-resuscitate orders, agitation or inability to cooperate, prisoners, or those who self-extubate are excluded and unlikely to benefit from the study interventions.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, randomized 1:1 pilot trial at Yale New Haven Hospital enrolling adults with systolic heart failure (ejection fraction ≤40%) who have been mechanically ventilated for more than 24 hours and are ready for planned extubation. Participants are randomized to extubation supported by either high-flow nasal cannula (HFNC) or noninvasive ventilation (NIV) using the Airvo 3 device. The primary outcomes are rates of reintubation and post-extubation respiratory failure, with reintubation decisions made by the attending physician. Results will inform the design and power calculations for a larger randomized controlled trial.

Why it matters

Potential benefit: If successful, this approach could reduce reintubation rates and respiratory complications after extubation in people with systolic heart failure.

How similar studies have gone: Prior ICU trials comparing HFNC and NIV in mixed patient groups have shown mixed but often encouraging results, but randomized data specifically in high-risk systolic heart failure patients are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* The patient is a male or non-pregnant female greater than or equal to 18 years of age
* The patient is ventilated for greater than 24 hours
* The patient has a systolic left ventricular dysfunction defined as an ejection fraction less than or equal to 40%
* The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

Exclusion Criteria:

* Patients actively being treated for a COPD exacerbation or known hypercapnia (PaCO2\>45) on last Arterial Blood Gas (ABG)
* Patients agitated or uncooperative state
* Patients with do-not-resuscitate orders
* Patients presenting with tracheostomies or anatomical abnormalities interfering with mask fit
* Patients are prisoners
* Patient self-extubates
* Patients with pre-existing NIV prescription (e.g., obstructive sleep apnea, neuromuscular disorders, advanced COPD)

Where it's running

  • Yale New Haven Hospital (CICU or MICU)
    New Haven, Connecticut, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.